A5008503600- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Hematological disorders and diagnostics
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Histone Deacetylase Inhibitors Research
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- RNA Research and Splicing
- RNA modifications and cancer
- Cytokine Signaling Pathways and Interactions
- Sarcoma Diagnosis and Treatment
- Blood disorders and treatments
- Protein Degradation and Inhibitors
- Kruppel-like factors research
The University of Texas MD Anderson Cancer Center
2016-2025
Scripps MD Anderson Cancer Center
2022-2024
Apellis Pharmaceuticals (United States)
2023
John Wiley & Sons (United States)
2016-2020
Hudson Institute
2020
Mayo Clinic
2016
The University of Texas at Austin
2010-2013
King Saud University
2013
Emory University
2013
Johns Hopkins Hospital
2012
Abstract BACKGROUND Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens, complete response rates are now reported to be > 80%, and long‐term survival range from 30% 45%. The current analysis updated results original hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone (Hyper‐CVAD) program, a median follow‐up time of 63 months. METHODS Between 1992 2000, 288 were treated...
Abstract Currently, there is no effective therapy for metastatic breast cancer after surgery, radiation, and chemotherapy have been used against the primary tumor. Because curcumin suppresses nuclear factor-κB (NF-κB) activation most chemotherapeutic agents activate NF-κB that mediates cell survival, proliferation, invasion, metastasis, we hypothesized would potentiate effect of in advanced inhibit lung metastasis. We tested this hypothesis using paclitaxel (Taxol)-resistant cells a human...
Abstract BACKGROUND Adult Burkitt‐type lymphoma (BL) and acute lymphoblastic leukemia (B‐ALL) are rare entities composing 1% to 5% of non‐Hodgkin lymphomas NHL) or ALL. Prognosis BL B‐ALL has been poor with conventional NHL ALL regimens, but improved dose‐intensive regimens. METHODS To evaluate the addition rituximab, a CD20 monoclonal antibody, intensive chemotherapy in adults B‐ALL, 31 patients newly diagnosed received hyper‐fractionated cyclophosphamide, vincristine, doxorubicin,...
Abstract Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this single-arm trial, in which patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) were treated azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously nivolumab 3 mg/kg on 14, every 4 6 weeks. For the seventy who treated, median age was 70 years (range, 22–90) number of prior therapies...
Purpose The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation monoclonal antibody therapy rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone). Other modifications (irrespective expression) included early anthracycline intensification, alterations number risk-adapted intrathecal treatments for CNS prophylaxis, additional and...
Background The physiopathology of sepsis continues to be poorly understood, and despite recent advances in its management, is still a life-threatening condition with poor outcome. If new diagnostic markers related pathogenesis will identified, specific therapies might developed mortality reduced. Small regulatory non-coding RNAs, microRNAs (miRNAs), were recently linked various diseases; the aim our prospective study was identify miRNAs that can differentiate patients early-stage from...
Abstract Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization clonal architecture essential to understand the evolutionary history tumor development and its association with treatment resistance. Here, using single-cell DNA sequencing, we report mutational histories 123 acute myeloid leukemia (AML) patients. The data reveals cell-level mutation co-occurrence enables reconstruction characterized linear branching patterns evolution,...
Phenotypic characterization of immune cells in the bone marrow (BM) patients with acute myeloid leukemia (AML) is lacking.T-cell infiltration was quantified on BM biopsies from 13 AML, and flow cytometry performed aspirates (BMAs) 107 AML who received treatment at The University Texas MD Anderson Cancer Center. authors evaluated expression inhibitory receptors (programmed cell death protein 1 [PD1], cytotoxic T-lymphocyte antigen 4 [CTLA4], lymphocyte-activation gene 3 [LAG3], T-cell...
Purpose The aim of the current study was to determine whether degree mutation clearance at remission predicts risk relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated AML who received intensive induction chemotherapy attained morphologic complete (CR) day 30 were studied. Pretreatment CR bone marrow analyzed using targeted capture DNA sequencing. We association between (MC) on basis variant allele frequency (VAF) (MC2.5: if...
Abstract Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires resistance. We performed gene/protein expression, metabolomic and methylation analyses of isogenic AML cell lines sensitive resistant to VEN, identified activation RAS/MAPK pathway, leading increased stability higher levels MCL-1 protein, as a major acquired mechanism VEN sustained survival maintained mitochondrial...